The ThermoBreast team is proud to announce the successful deployment of ThermoMind’s innovative Vision One device at Assuta Medical Centers in Haifa, Israel. This marks a major milestone in our groundbreaking international ThermoBreast clinical study, which aims to revolutionise women’s health through advanced breast cancer screening technology. The deployment of the Vision One device is the result of a collaborative effort between the teams at Assuta Medical Centers and ThermoMind, who have worked tirelessly to navigate complex processes and prioritise women’s health.
Leading the way at Assuta Medical Centers is Michal Guindy, whose unwavering support and guidance have been invaluable in making this crucial phase of the clinical trial a reality. Efrat Slonim and Orna Vidal have also played key roles in ensuring the success of this process. This milestone is only the beginning of our journey towards transforming women’s healthcare.
We have many more clinical sites in the pipeline, and we are excited to continue our efforts to start the ThermoBreast clinical trial in the remaining partners’ clinics and hospitals.
